Inhibikase Therapeutics, Inc. IKT
We are a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension ("PAH"), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as "c-Kit", has been implicated. Our lead product candidate is IKT-001, a prodrug of imatinib mesylate ("imatinib"), for PAH which is an orphan indication. Imatinib was first approved in the United States in 2001 for various cancers and blood disorders and, following more than 20 years of clinical use, has a well-characterized safety profile with the first reported use of imatinib in PAH occurring in 2005. PAH is a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance that affects approximately 50,000 Americans. We have completed a non-human primate safety study and a bioequivalence clinical study in healthy volunteers to determine the doses of IKT-001 that are equivalent to imatinib. Our Phase 3 clinical study, named IMPROVE-PAH (IKT-001 for Measuring Pulmonary Vascular Resistance and Outcome Variables in a Phase 3 Evaluation of PAH), has been initiated with the activation of a small number of sites and the recent commencement of patient pre-screening activities at those sites.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $0 | $260.5K | $123.4K | $3.1M | $698.5K | — |
| R&D | $29.8M | $17.2M | $13.6M | $12.0M | $11.4M | $893.8K | — |
| SG&A | $23.6M | $11.4M | $6.7M | $6.2M | $6.5M | $2.6M | — |
| Total operating expenses | $52.0M | $28.6M | $20.4M | $18.3M | $17.9M | $3.5M | — |
| Operating income | -$52.0M | -$28.6M | -$20.1M | -$18.1M | -$14.8M | -$2.8M | — |
| Interest expense | $3.7M | $1.1M | $1.1M | $74.5K | $19.9K | $29.4K | — |
| Pre-tax income | -$48.3K | -$27.5K | — | — | — | — | — |
| Income tax | $0 | $0 | — | — | — | — | — |
| Net income | -$48.3M | -$27.5M | -$19.0M | -$18.1M | -$14.8M | -$2.8M | — |
| EPS, basic | -0.49 | -1.16 | -3.16 | -4.28 | -0.81 | — | — |
| EPS, diluted | -0.49 | -1.16 | -3.16 | -4.28 | -0.81 | -0.35 | — |
| Shares, diluted (wtd. avg.) | 98.3M | 23.7M | 6.0M | 4.2M | 18.2M | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $178.8M | $97.5M | $9.2M | $7.2M | $40.8M | $14.0M | $18.5K |
| Short-term investments | $39.5M | $41.1M | $4.1M | $15.9M | $0 | — | — |
| Total current assets | $180.1M | $98.5M | $14.2M | $24.4M | $42.5M | — | — |
| Property, plant and equipment | $0 | $47.1K | $73.4K | $236.5K | $0 | — | — |
| Total assets | $181.2M | $98.6M | $14.5M | $24.9M | $42.5M | $14.8M | — |
| Accounts payable | $1.2M | $943.0K | $646.8K | $1.2M | $1.1M | $1.7M | — |
| Total current liabilities | $8.3M | $3.7M | $3.4M | $3.7M | $4.1M | $4.7M | — |
| Long-term debt | — | — | $381.8K | — | $248.9K | — | — |
| Total liabilities | $8.3M | $3.7M | $3.5M | $3.9M | $4.1M | $5.0M | — |
| Retained earnings | -$142.7M | -$94.4M | -$66.9M | -$47.9M | -$29.8M | $15.0M | — |
| Total equity | $172.9M | $94.9M | $11.0M | $21.0M | $38.4M | $9.8M | -$4.5M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$27.8M | -$19.1M | -$18.1M | -$17.4M | -$14.3M | -$1.1M | — |
| Depreciation and amortisation | $60.5K | $26.3K | $177.4K | $6.7K | $0 | — | — |
| Stock-based compensation | $15.3M | $8.1M | $500.1K | $458.1K | $1.5M | $573.7K | — |
| Capital expenditure | $13.4K | $0 | $14.2K | $243.3K | $0 | — | — |
| Investing cash flow | $2.1M | -$37.0M | $11.7M | -$16.0M | $0 | — | — |
| Financing cash flow | $108.5M | $103.5M | $8.4M | -$204.8K | $41.1M | $15.1M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-197177.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $698.5K | $3.1M | $123.4K | $260.5K | $0 | — |
| Gross profit | — | — | — | — | — | — | — |
| Net income | — | -$2.8M | -$14.8M | -$18.1M | -$19.0M | -$27.5M | -$48.3M |
Recent filings and events
- Auditor changed The company changed auditors. Sometimes routine; historically one of the more reliable warnings that something is wrong. Item 4.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Regulation FD disclosure Item 7.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $237.48B | 30.9x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $193.48B | 23.0x | 2.4% |
| MRNA | Moderna, Inc. | $79.89B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $40.08B | — | — |
| BIIB | BIOGEN INC. | $37.01B | 28.5x | 2.2% |
| EXEL | EXELIXIS, INC. | $15.99B | 23.2x | 7.0% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $14.51B | 30.6x | 21.4% |
| HALO | HALOZYME THERAPEUTICS, INC. | $14.26B | 49.1x | 37.6% |